ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,948Medicare Part D Prescriptions Filled, Including Refills

Rank: 24 out of 134

$572K Total Retail Price of All Prescriptions

Rank: 24 out of 134

442 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
28% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Idaho
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 442 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

14% of this provider’s 442 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 8,880 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Idaho
LEVOTHYROXINE SODIUM 541 491 1 1
SIMVASTATIN 485 444 2 2
HYDROCODONE-ACETAMINOPHEN 338 284 S3 3 5
AMLODIPINE BESYLATE 332 315 4 6
OMEPRAZOLE 328 315 5 3
LISINOPRIL 306 279 6 4
WARFARIN SODIUM 251 240 7 8
FUROSEMIDE 229 213 8 7
ZOLPIDEM TARTRATE 198 171 9 15
CITALOPRAM HBR 195 164 10 14
GABAPENTIN 168 126 11 12
METOPROLOL SUCCINATE 163 163 12 16
ALENDRONATE SODIUM 159 159 13 21
ATORVASTATIN CALCIUM 151 135 14 18
METFORMIN HCL 148 132 15 9
LOSARTAN POTASSIUM 135 134 16 11
GLIMEPIRIDE 130 130 17 36
SERTRALINE HCL 127 110 18 24
METOPROLOL TARTRATE 122 121 19 17
DIOVAN 118 105 20 55
TRAZODONE HCL 118 90 20 23
ALLOPURINOL 108 91 22 25
POTASSIUM CHLORIDE 85 85 23 10
DONEPEZIL HCL 84 72 24 30
HYDROCHLOROTHIAZIDE 83 80 25 13
PREDNISONE 81 74 26 28
ATENOLOL 80 78 27 19
CLONIDINE HCL 79 79 28 60
RANITIDINE HCL 76 76 29 48
TAMSULOSIN HCL 72 72 30 26
OXYBUTYNIN CHLORIDE ER 71 62 31 106
PREMARIN 65 64 R 32 84
ESTRADIOL 65 56 R 32 66
SPIRONOLACTONE 61 51 34 29
METFORMIN HCL ER 61 58 34 43
TRAMADOL HCL 60 60 36 22
PRAVASTATIN SODIUM 58 58 37 20
DIGOXIN 58 58 37 31
PAROXETINE HCL 57 57 39 46
TRIAMTERENE-HCTZ 56 56 40 40
FLUOXETINE HCL 55 50 41 42
ACTOS 54 54 42 81
LISINOPRIL-HYDROCHLOROTHIAZIDE 53 41 43 45
FENTANYL 51 50 S2 44 41
LOSARTAN-HYDROCHLOROTHIAZIDE 50 32 45 50
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 21, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.